Assistant Professor, Medicine - Oncology, Stanford University Medical Center
Oncology
Dr. Kristen N. Ganjoo, MD
|
|
Give Review
Kristen Ganjoo practices Oncology. She went to University of South Alabama College of Medicine. University of South Alabama College of Medicine is ranked 83 in research and 35 in primary care medicine She received awards:"CMS Meaningful Use Stage 1 Certification". Dr. Kristen N. Ganjoo is a published MD as well. She has 41 publications published. The latest was: SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma. Doctor Kristen N. Ganjoo, MD is registered with Medicare and accepts Medicare payments.
Publications
- Phase 1/2 Study of Ocaratuzumab, an Fc-Engineered Humanized Anti-CD20 Monoclonal Antibody, in Low-Affinity FcγRIIIa Patients with Previously Treated Follicular Lymphoma.
- Gastrointestinal stromal Tumors, version 2.2014.
- A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyoSarcoma, osteo...
- Active Idiotypic Vaccination Versus Control Immunotherapy for Follicular Lymphoma.
- Soft tissue Sarcoma, version 2.2014.
- Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-Cell or natural killer Cell neoplasms: an East...
- The Treatment Outcome for Adult Patients with Ewing's Sarcoma.
- Chest wall leiomyosarcoma after breast-conservative therapy for early-stage breast Cancer in a young woman with li-fraumeni syndrome.
- A Phase 1 Study of AME-133v (LY2469298) an Fc-Engineered Humanized Monoclonal Antibody in Fc?RIIIa-Genotyped Patients with Previously Treated Follicular Lymphoma.
- R1507, a Monoclonal Antibody to the Insulin-Like Growth Factor 1 Receptor in Patients With Recurrent or Refractory Ewing Sarcoma Family of Tumors: Results of a Phase I...
- A Phase I Study of the Safety and Pharmacokinetics of the Hypoxia-Activated Prodrug TH-302 in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma.
- New developments in targeted therapy for soft tissue Sarcoma.
- NCCN Task Force report: update on the management of patients with gastrointestinal stromal Tumors.
- Coordinate expression of colony-stimulating factor-1 and colony-stimulating factor-1-related proteins is associated with poor prognosis in gynecological and nongynecol...
- A phase II study of single agent gemcitabine in relapsed or refractory follicular or small lymphocytic non-Hodgkin Lymphomas: a Hoosier Oncology Group Study.
- Unusual locations of involvement by malignancies: Case 1. Testicular plasmacytoma.
- Germ Cell tumor associated primitive neuroectodermal tumors.
- Results of modern therapy for patients with mediastinal nonseminomatous germ Cell tumors.
- Lung Cancer presenting with solitary bone metastases. Case 1: metastatic adenocarcinoma to the patella.
- Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma.
- Primary mediastinal nonseminomatous germ Cell tumors: the influence of postchemotherapy pathology on long-term survival after surgery.
- Opportunistic enteroviral meningoencephalitis: an unusual treatable complication of rituximab therapy.
- The importance of angiogenesis markers in the outcome of patients with diffuse large B cell Lymphoma: a retrospective study of 97 patients.
- Non-Hodgkin lymphoma of the Breast.
- Antiangiogenesis: a new approach to the treatment of Lymphoma.
- Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell Lymphoma: safety, biomarker and pharmacokinetic analysis.
- Phase II clinical studies of denileukin diftitox diphtheria toxin fusion protein in patients with previously treated chronic lymphocytic Leukemia.
- Antiangiogenesis agents in the treatment of soft tissue Sarcomas.
- Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin Lymphoma: results from a Multicenter Study.
- Acute myeloid leukemia in patients with gastrointestinal stromal tumors treated with Gleevec.
- Trabectedin: an antiCancer drug from the sea.
- Review of erlotinib in the treatment of advanced non-small cell lung Cancer.
- 131I-Tositumomab (Bexxar) vs. 90Y-Ibritumomab (Zevalin) therapy of low-grade refractory/relapsed non-Hodgkin Lymphoma.
- Current and emerging pharmacological treatments for gastrointestinal stromal tumour.
- A phase II first-line study of gemcitabine, carboplatin, and bevacizumab in advanced stage nonsquamous non-small cell lung Cancer.
- Maintenance Bevacizumab is Associated With Increased Hemoglobin in Patients With Advanced, Nonsquamous, Non-Small Cell Lung Cancer.
- A phase I study of weekly gemcitabine and docetaxel in patients with advanced Cancer: a Hoosier Oncology Group Study.
- Phase II study of gemcitabine plus docetaxel in advanced pancreatic Cancer: a Hoosier Oncology Group study.
- SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced Sarcoma.
- Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic LipoSarcoma or LeiomyoSarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Rando...
Schools
University Of South Alabama College Of Medicine
Indiana University
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anemia
- Bladder Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
Indiana University School of Medicine -
University of South Alabama College of Medicine
Hospital
-
Stanford Health Care
Drug Facts
| NPI NUMBER | 1669563391 | |
| NPPES Provider LastName | GANJOO | |
| NPPES Provider FirstName | KRISTEN | |
| NPPES Provider ZIPCode | 94305 | |
| NPPES Provider State | CA | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 250.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 14.0 | |
| Percent Opioid Claims | 5.6 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1669563391 |
| Last Name Of The Provider | GANJOO |
| First Name Of The Provider | KRISTEN |
| View All |
Similar Doctors
|
|
Dr. Alice E. Guardino, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joshua Brody, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Melinda L. Telli, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Paula Kushlan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Harlan A. Pinto, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gilbert Chu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Eric W. Humke, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Myron M. Turbow, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. George A. Fisher Jr., MD |
|
|
Sandhya Srinivas, MB
This Doctor is OpenDoctor Recommended.
|